PL1781321T3 - Sposób leczenia raka zawierający antagonistę VEGF-B - Google Patents

Sposób leczenia raka zawierający antagonistę VEGF-B

Info

Publication number
PL1781321T3
PL1781321T3 PL05764158T PL05764158T PL1781321T3 PL 1781321 T3 PL1781321 T3 PL 1781321T3 PL 05764158 T PL05764158 T PL 05764158T PL 05764158 T PL05764158 T PL 05764158T PL 1781321 T3 PL1781321 T3 PL 1781321T3
Authority
PL
Poland
Prior art keywords
vegf
antagonist
treating cancer
cancer
treating
Prior art date
Application number
PL05764158T
Other languages
English (en)
Inventor
Andrew Nash
Felicity Meredith Dunlop
Manuel Baca
Louis Jerry Fabri
Pierre David Scotney
Original Assignee
Zenyth Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35786817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1781321(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zenyth Operations Pty Ltd filed Critical Zenyth Operations Pty Ltd
Publication of PL1781321T3 publication Critical patent/PL1781321T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL05764158T 2004-08-02 2005-08-02 Sposób leczenia raka zawierający antagonistę VEGF-B PL1781321T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59815904P 2004-08-02 2004-08-02
US63444404P 2004-12-09 2004-12-09
EP05764158.1A EP1781321B1 (en) 2004-08-02 2005-08-02 A method of treating cancer comprising a vegf-b antagonist
PCT/AU2005/001152 WO2006012688A1 (en) 2004-08-02 2005-08-02 A method of treating cancer comprising a vegf-b antagonist

Publications (1)

Publication Number Publication Date
PL1781321T3 true PL1781321T3 (pl) 2014-07-31

Family

ID=35786817

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05764158T PL1781321T3 (pl) 2004-08-02 2005-08-02 Sposób leczenia raka zawierający antagonistę VEGF-B

Country Status (9)

Country Link
US (2) US8822644B2 (pl)
EP (2) EP2476427B1 (pl)
JP (3) JP5014130B2 (pl)
AU (1) AU2005269265B2 (pl)
CA (1) CA2575901C (pl)
DK (2) DK1781321T3 (pl)
ES (1) ES2456943T3 (pl)
PL (1) PL1781321T3 (pl)
WO (1) WO2006012688A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2596210C (en) 2005-02-03 2014-07-08 Topotarget Uk Limited Combination therapies using hdac inhibitors
US8835501B2 (en) 2005-05-13 2014-09-16 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2009040517A2 (en) 2007-09-25 2009-04-02 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
CN110372792A (zh) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
EP2670778A1 (en) * 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
US20130085095A1 (en) * 2011-09-29 2013-04-04 Trustees Of Boston University Protein complementation regulators
WO2013161814A1 (ja) * 2012-04-23 2013-10-31 ジーンフロンティア株式会社 抗ヒトｃｄ６９抗体、及びその医薬用途
EP3381943B1 (en) 2012-07-25 2022-03-16 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2014045266A1 (en) 2012-09-24 2014-03-27 Ulf Eriksson Treatment of type 2 diabetes and related conditions
KR102339724B1 (ko) * 2013-11-28 2021-12-17 씨에스엘 리미티드 신장병증의 치료 방법
JP6553618B2 (ja) * 2013-12-18 2019-07-31 シーエスエル リミティド 創傷を治療する方法
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
RU2744909C2 (ru) * 2014-11-17 2021-03-17 СиЭсЭл ЛИМИТЕД Способ лечения или предотвращения инсульта
RU2018139893A (ru) * 2016-04-21 2020-05-21 СиЭсЭл ЛИМИТЕД Способ лечения или предупреждения болезней печени
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2023115112A1 (en) * 2021-12-20 2023-06-29 CSL Innovation Pty Ltd Protein formulations and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000A (en) * 1845-04-16 Combined lock and latch
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5359051A (en) 1990-01-11 1994-10-25 Isis Pharmaceuticals Compounds useful in the synthesis of nucleic acids capable of cleaning RNA
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US20040102389A1 (en) 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
WO1999058126A1 (en) * 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
AU4662400A (en) * 1999-04-26 2000-11-10 Helsinki University Licensing Ltd Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
US6942981B1 (en) * 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003062788A2 (en) 2002-01-17 2003-07-31 Genetix Pharamaceuticals, Inc. Method for inhibiting angiogenesis
US20040005671A1 (en) * 2002-05-17 2004-01-08 Amrad Operations Pty Ltd. Immunointeractive molecules
US20030232439A1 (en) 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法

Also Published As

Publication number Publication date
ES2456943T3 (es) 2014-04-24
AU2005269265A1 (en) 2006-02-09
EP2476427A3 (en) 2012-10-03
US20140363445A1 (en) 2014-12-11
DK2476427T3 (en) 2018-05-07
JP5014130B2 (ja) 2012-08-29
DK1781321T3 (da) 2014-04-14
AU2005269265B2 (en) 2012-01-12
CA2575901C (en) 2015-01-27
EP1781321B1 (en) 2014-01-08
EP2476427B1 (en) 2018-01-17
US8822644B2 (en) 2014-09-02
EP1781321A1 (en) 2007-05-09
JP2014224149A (ja) 2014-12-04
HK1103654A1 (en) 2007-12-28
WO2006012688A1 (en) 2006-02-09
EP1781321A4 (en) 2009-11-18
CA2575901A1 (en) 2006-02-09
JP2012036189A (ja) 2012-02-23
JP2008508325A (ja) 2008-03-21
JP5662912B2 (ja) 2015-02-04
US20080260729A1 (en) 2008-10-23
EP2476427A2 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
PL1781321T3 (pl) Sposób leczenia raka zawierający antagonistę VEGF-B
GB0308731D0 (en) Method of radiotherapy
IL179139A0 (en) Method for treating multiple sclerosis
ZA200508427B (en) Methods for treating interleuking-6 related diseases
GB0416871D0 (en) Well characterisation method
PL2302097T3 (pl) Metoda obróbki powierzchni
GB0416523D0 (en) Method of manufacture
ZA200705059B (en) Cancer treatment method
GB0422004D0 (en) Method of deprotection
EP1734334A4 (en) EXPLOSION PROCESS
IL176919A0 (en) Methods and compositions for treating cancer
EP1755394A4 (en) METHOD OF TREATING CANCER
EP1725237A4 (en) ANTI-ALCOHOLIC TREATMENT
GB2435169B (en) Process for treating an underground formation
GB0424005D0 (en) Method of coating
IL179323A0 (en) Cancer treatment method
EP1742629A4 (en) METHOD FOR TREATING ALCOHOLISM
GB0413346D0 (en) Treating cancer
GB2464421B (en) Method of forming tubing
IL179359A0 (en) Cancer treatment method
EP1809276A4 (en) PROCESSING PROCESS
GB0426196D0 (en) Methods of treatment
EP1802617A4 (en) CANCER TREATMENT METHOD
HUP0401172A2 (en) Method for arming composit-fabrication of open-air located objects
HU0401136D0 (en) Method for post-blinding of gas-plumbing